In a nutshell This study wanted to find out which of three medicines was best for treating breast cancer, palbociclib (Ibrance), ribociclib (Kisquali), or abemaciclib (Verzenio). The study found that the medications all worked equally as well, but there were different side effects for each one. Some background Estrogen receptor positive (ER+) breast...Read More
Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor
In a nutshell This study wanted to find out if the risk of patients with breast cancer developing a blood clot was higher if they were treated with aromatase inhibitors, or tamoxifen (Nolvadex). The study found that the patients treated with tamoxifen had a higher risk of developing blood clots compared to those treated with aromatase...Read More
In a nutshell This study wanted to analyse how treatment with everolimus (Afintor) and exemestane (Aromasin) is performed in patients with breast cancer, and if there are any side effects. The study found that treatment occured for an average of 28 .5 weeks, and side effects were seen in a number of patients, including...Read More
In a nutshell This study wanted to find out if joint pain is associated with falling down in patients with breast cancer who were treated with aromatase inhibitors. The study found that the patients who reported having joint pain were more likely to have a fall than those who had no joint pain. Some background Aromatase inhibitors are medications...Read More
In a nutshell This study wanted to find out if treating breast cancer with everolimus (Afintor) and endocrine therapy is better than only treating with endocrine therapy. The study found that using everolimus in addition to endocrine therapy had a significant benefit to survival in these patients. Some background Breast cancer is classified into types...Read More
In a nutshell This article investigated the safety and effectiveness of adding Omega-3 fatty acid (O3-FA) to the management of joint pain in patients with breast cancer treated with aromatase inhibitors. The authors concluded that the addition of O3-FA is safe and gave the greatest benefit to patients who were obese. Some background...Read More
In a nutshell This study investigated the overall survival rates of people with breast cancer who were treated with either palbociclib (Ibrance) plus fulvestrant (Faslodex), or just fulvestrant. The study found that the patients who received both palbociclib and fulvestrant had a longer overall survival compared to the group who only received...Read More
10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.
In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...Read More
In a nutshell This study examined if the presence of certain genes had an effect on endocrine (hormone) treatment alone compared to chemoendocrine (chemotherapy and hormone) treatment for breast cancer. The study concluded that endocrine and chemoendocrine had the same effectiveness in women with certain genetic factors. Some background Breast cancer...Read More
In a nutshell This study aimed to find out if the breast cancer treatment palbociclib (Ibrance) works better alone, or in combination with other endocrine therapies (drugs which act on hormone receptors) used to treat estrogen receptor positive (ER+ – a hormone receptor found on the tumor) breast cancer. The authors found that treating women...Read More
In a nutshell This study aimed to compare anastrozole (Arimidex) and tamoxifen (Nolvadex) in the treatment of breast cancer. This study concluded that anastrozole is effective in the treatment of breast cancer. Some background Breast cancer is classified into different subtypes depending on the presence or absence...Read More
Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.
In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone. Some...Read More